ArticleImmunoTargets and therapy2025
Profiling Shared Cytotoxic Immune Signatures in SLE-Associated Coronary Injury Through Transcriptomics and Machine Learning.
Article in ImmunoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic signatures and immune microenvironment of acute rejection after heart transplantation: an integrated bioinformatics analysis.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigated shared molecular pathways linking systemic lupus erythematosus (SLE) and coronary artery disease (CAD) to uncover mechanisms of coronary injury in SLE. Patients and Methods: Bulk transcriptomic datasets (GSE45291 for SLE, GSE61145 for CAD) were analyzed to identify differentially expressed genes (DEGs), immune cell infiltration patterns, and co-expression networks. A diagnostic model was constructed and validated using external cohorts (GSE49454 for SLE, GSE179789 for CAD). Machine learning prioritized core genes, validated in both external cohorts and in SLE patients with coronary injury (GSE264125). Cellular localization and intercellular communication were explored by analyzing single-cell RNA-seq data (GSE135779). qPCR was used to validate the gene expression in peripheral blood mononuclear cells (PBMCs) from patients. Results: We identified 146 common DEGs enriched in immune pathways related to cell toxicity, and found shared dysregulation in cytotoxic lymphocytes such as natural killer (NK) cells and CD8 Conclusion: SLE and CAD share a cytotoxic lymphocyte-driven molecular axis, with GZMK/KLRK1-mediated immune dysregulation as a key contributor to coronary injury in SLE. GZMK and KLRK1 may represent promising biomarkers for early detection and risk stratification of SLE-associated coronary complications. Notably, the discrimination (AUC=1.000) was observed in a limited subgroup of SLE patients with coronary microvascular dysfunction (n=4), warranting further validation in expanded cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.